Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Petra Jankowska

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Endocrinology and Metabolism Clinics of North America|January 30, 2008
Radiotherapy for pituitary adenomasMichael Brada, Petra Jankowska
Journal of Medical Imaging and Radiation Sciences|May 4, 2019
A Pilot Study Evaluating the Effectiveness of Dual-Registration Image-Guided Radiotherapy in Patients with Oropharyngeal CancerSimon Goldsworthy, Marcus Leslie-Dakers, Steven Higgins, et al.
Lung Cancer (Amsterdam, Netherlands)|April 18, 2026
Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigmsAshley Horne, Igor Gomez-Randulfe, Amy Ford, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2026
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)Omar Abdel-Rahman, Paul Taylor, Mary O'Brien, et al.
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
British Journal of Cancer|December 5, 2024
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapySanjay Popat, Adam Januszewski, Mary O'Brien, et al.
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
Clinical and Translational Radiation Oncology|July 6, 2021
A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemicIfigenia Vasiliadou, David Noble, Andrew Hartley, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialHye Ryun Kim, Marc Oliva, Sebastien Salas, et al.
International Journal of Cancer|April 30, 2024
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UKIfigenia Vasiliadou, Derek Grose, Christina Wilson, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Endocrinology and Metabolism Clinics of North America|January 30, 2008
Radiotherapy for pituitary adenomasMichael Brada, Petra Jankowska
Journal of Medical Imaging and Radiation Sciences|May 4, 2019
A Pilot Study Evaluating the Effectiveness of Dual-Registration Image-Guided Radiotherapy in Patients with Oropharyngeal CancerSimon Goldsworthy, Marcus Leslie-Dakers, Steven Higgins, et al.
Lung Cancer (Amsterdam, Netherlands)|April 18, 2026
Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigmsAshley Horne, Igor Gomez-Randulfe, Amy Ford, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2026
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)Omar Abdel-Rahman, Paul Taylor, Mary O'Brien, et al.
The Lancet. Oncology|October 18, 2015
Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trialR Paul Symonds, Charlie Gourley, Susan Davidson, et al.
British Journal of Cancer|December 5, 2024
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapySanjay Popat, Adam Januszewski, Mary O'Brien, et al.
Journal for Immunotherapy of Cancer|September 8, 2025
Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancerCaroline Even, Kevin J Harrington, Erminia Massarelli, et al.
Clinical and Translational Radiation Oncology|July 6, 2021
A multi-centre survey reveals variations in the standard treatments and treatment modifications for head and neck cancer patients during Covid-19 pandemicIfigenia Vasiliadou, David Noble, Andrew Hartley, et al.
European Journal of Cancer (Oxford, England : 1990)|June 4, 2026
Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trialHye Ryun Kim, Marc Oliva, Sebastien Salas, et al.
International Journal of Cancer|April 30, 2024
The use of pembrolizumab monotherapy for the management of head and neck squamous cell carcinoma (HNSCC) in the UKIfigenia Vasiliadou, Derek Grose, Christina Wilson, et al.
Pageof 1